Objective: Trimethoprim-sulfamethoxazole prophylaxis is recommended for HIVexposed infants until breastfeeding ends and HIV infection has been excluded. Extending prophylaxis with a focus on preventing malaria may be beneficial in high transmission areas. We investigated three regimens for the prevention of malaria in young HIV-exposed children.
Introduction
Due to the success of prevention of mother-to-child transmission (PMTCT) interventions [1] , HIV-exposed uninfected (HEU) children (HIV-negative children born to HIV-infected mothers) are a growing population in Africa. Importantly, these children have been reported to have an increased risk of morbidity and mortality compared with children born to HIV-uninfected mothers [2] [3] [4] [5] [6] . This association is thought to be mediated through several factors, including impaired immunity [7] [8] [9] [10] , premature cessation of breastfeeding [11] and indirect factors such as increased parental mortality, exposure to maternal infections and poverty.
Given the increased morbidity and mortality in HEU children and high rates of maternal-to-child transmission of HIV in the absence of PMTCT interventions, the WHO recommends placing HEU children on trimethoprim-sulfamethoxazole prophylaxis starting at 6 weeks of age [12] . This recommendation was initially made following studies in HIV-infected adults showing that trimethoprim-sulfamethoxazole effectively reduces morbidity by preventing opportunistic infections [13] . Subsequent studies showed that trimethoprim-sulfamethoxazole prophylaxis reduces morbidity in HIVinfected [14] [15] [16] and HEU children [11, 17, 18] . Current guidelines recommend discontinuation of trimethoprimsulfamethoxazole prophylaxis in HEU children after the period of HIV exposure (i.e. after breastfeeding ends and HIV infection has been excluded) [12] .
One of the principal benefits of trimethoprim-sulfamethoxazole prophylaxis in individuals living in sub-Saharan Africa is the prevention of malaria. Several studies have shown a benefit of trimethoprim-sulfamethoxazole in preventing malaria in HIV-infected and uninfected children and adults [15, 19, 20] . Further, there is evidence of continued benefit of trimethoprim-sulfamethoxazole prophylaxis in immune-reconstituted HIV-infected children and adults on antiretroviral therapy when administered beyond current guideline recommendations, largely through prevention of malaria [21, 22] . We previously showed that extending trimethoprim-sulfamethoxazole prophylaxis beyond breastfeeding cessation to 24 months of age was well tolerated and resulted in 39% protective efficacy against malaria among HEU children living in a high-malaria transmission setting [23] . In that study, trimethoprim-sulfamethoxazole did not have significant benefit against diarrhoea or respiratory tract infections, two common infectious syndromes associated with HIV infection. We therefore asked whether we could improve upon the efficacy of daily trimethoprim-sulfamethoxazole in preventing malaria in HEU children beyond the period of HIV exposure by comparing it with two strategies of intermittent preventive therapy (IPT): monthly sulfadoxine pyrimethamine, another antifolate medication used for prevention of malaria during pregnancy and in childhood [24] [25] [26] , or monthly dihydroartemisinin-piperaquine, a regimen with excellent treatment efficacy against malaria and a prolonged posttreatment prophylactic effect [27] . Children were randomized after the cessation of breastfeeding to one of these three chemoprevention strategies (daily trimethoprim-sulfamethoxazole, monthly sulfadoxine pyrimethamine or monthly dihydroartemisinin-piperaquine) or to no chemoprevention (discontinue trimethoprim-sulfamethoxazole prophylaxis) through 24 months of age, and then followed for an additional year after the intervention.
Materials and methods

Study design, site and population
We performed a randomized, controlled, open-label trial comparing the efficacy and safety of three regimens versus no therapy for the prevention of malaria in HEU children living in Tororo District, eastern Uganda, an area with intense year-round malaria transmission and an entomological inoculation rate estimated at 125 infectious bites per person-year in 2011-2012 [28] .
Convenience sampling was used to enrol a cohort of 200 infants 4-5 months of age from the Tororo District Hospital Maternal and Child Health clinic between June 2010 and July 2011. Eligibility criteria included confirmed HIV-positive status of biological mother; confirmed negative HIV DNA PCR test of infant at time of enrolment; infant actively breastfeeding at the time of enrolment; residency within 30 km of the study clinic with no intention of moving outside the study area; agreement to come to the study clinic for any illness and to avoid medications outside the study protocol; provision of informed consent by parent/guardian; no history of allergy or sensitivity to any study drugs; absence of active medical problem requiring in-patient evaluation or chronic medical conditions requiring frequent attention; and absence of clinically significant electrocardiogram abnormalities, family history of long QT syndrome or current use of drugs that prolong the QT interval. Only one eligible child was enrolled per household, and at enrolment, all children were prescribed daily trimethoprim-sulfamethoxazole prophylaxis for the duration of breastfeeding as standard of care and each household was given two long-lasting insecticide-treated bednets (ITNs).
Study drugs and treatment allocation
Six weeks following cessation of breastfeeding, a DNA PCR test was done for each participant and those who remained HIV uninfected were randomized. A randomization list using permuted variable-sized blocks of 4, 8 and 12 was computer generated by a member of the study not directly involved in patient care. Randomization was done using premade, consecutively numbered, sealed envelopes. Treatment allocation was performed by nurses not involved with patient care. Study drugs were dosed as trimethoprim-sulfamethoxazole (Co-trimoxazole; Kampala Pharmaceutical Industries, Kampala, Uganda) single dose once daily, sulfadoxine pyrimethamine (Kamsidar; Kampala Pharmaceutical Industries) single dose each month and dihydroartemisinin-piperaquine (Duo-Cotexin; Holley-Cotec, Beijing, China) once daily for three consecutive days each month, each provided for administration at home according to weight-based guidelines. At the time of treatment allocation, parents/guardians were given a 2-month supply of drugs and a diary with dates for dosing and check-offs to indicate administration. Parents/ guardians were instructed to readminister drugs if children vomited within 30 min of administration and to bring children to the clinic if they vomited again. During each visit to the study clinic, parent/guardians were questioned about study drug use.
Study procedures
Participants received all of their medical care at a designated study clinic open every day. Children who presented with a documented fever (tympanic temperature >38.08C) or a history of fever in the previous 24 h had blood obtained by finger prick for a thick blood smear. If the smear was positive, the patient was diagnosed with malaria and a complete blood count (CBC) and thin blood smear for parasite speciation were performed. Episodes of uncomplicated malaria were treated with artemether-lumefantrine. Artemether-lumefantrine was administered twice a day for 3 days, with the first dose each day directly observed in the clinic and the second administered at home. Episodes of complicated malaria (severe malaria or danger signs) [29] or treatment failures occurring within 14 days of prior therapy were treated with quinine. Routine evaluations, including thick blood smears and assessment of adherence with ITNs and study drugs, were done monthly. CBC, glucose and alanine aminotransferase (ALT) levels were assessed every 4 months. HIV DNA PCR tests were done every 60 days during breastfeeding, at 6 weeks following cessation of breastfeeding and at 18 months of age. Adverse events were assessed and graded according to severity (mild, moderate, severe, life-threatening) using standardized criteria at every clinic visit. Diagnosis of incident episodes of nonmalarial illnesses, including diarrhoeal illnesses and respiratory tract infections, was based on a prespecified list of diagnostic criteria developed by the study team. Medications with antimalarial activity were avoided for the treatment of nonmalarial illnesses when possible. Antihelminthics, iron sulphate and vitamin A were prescribed following Integrated Management of Childhood Illness guidelines.
Chemoprevention was stopped at 24 months of age and study participants were followed-up 1 additional year until they reached 36 months of age. Study participants were prematurely withdrawn from the study for documented HIV infection by DNA PCR (these children were referred to an appropriate HIV care centre), movement out of the study area, failure to be seen in the study clinic for more than 60 consecutive days, withdrawal of informed consent or inability to comply with the study schedule and procedures.
Laboratory procedures
Thick and thin blood smears were stained with 2% Giemsa for 30 min. Parasite density was estimated by counting the number of asexual parasites per 200 white blood cells and assuming a white blood cell count of 8000 cells/ml. A smear was deemed negative if no parasites were seen in 100 high powered fields. Microscopy quality control included re-reading all blood smears and resolution of any discrepancies by a third microscopist. Piperaquine drug levels were measured from capillary blood collected on filter paper on the day malaria was diagnosed among study participants randomized to monthly dihydroartemisinin-piperaquine, as previously described [30] .
Statistical analysis
The study was designed to test the hypotheses that chemoprevention will lower the incidence of malaria compared to no chemoprevention, and that the optimal chemoprevention regimen will be dihydroartemisininpiperaquine. We assumed that the incidence of malaria would be 1.85 episodes per person year with TS based on a prior cohort study in the same area [23] , and thus, that we would need to enrol 50 participants in each arm to detect a reduction in the incidence of malaria in either the monthly sulfadoxine pyrimethamine or dihydroartemisinin-piperaquine arms (two-sided significance level ¼ 0.05) compared with the daily trimethoprim-sulfamethoxazole arm of 48% or greater with 80% power at 95% significance (two-sided), allowing for 10% loss to follow-up.
Data were double-entered and verified in Microsoft Access and statistical analyses performed using Stata, version 12 (Stata-Corp, College Station, Texas, USA). All analyses used an intention-to-treat approach for participants who were randomized to therapy. The primary outcome was the incidence of malaria, defined as the number of incident episodes per time at risk, during the period the intervention was given. Treatments within 14 days of a prior episode were not considered incident events. Time at risk was from the day following the initiation of study drugs to the last day of observation, minus 14 days after each treatment for malaria. Secondary outcomes included the incidence of complicated malaria, hospitalizations, diarrhoeal illnesses, respiratory tract infections and serious adverse events or adverse events of moderate or greater severity (grade 3-4); the prevalence of moderate-severe anaemia (haemoglobin <8 gm/dl) at the time of each episode of malaria and upon routine testing every 4 months and the prevalence of parasitemia and gametocytemia seen in monthly routine blood smears. To assess the impact of chemoprevention on the development of naturally acquired immunity, the incidence of malaria, complicated malaria and hospitalizations was compared after the intervention was stopped, between 24 and 36 months of age.
Incidence outcomes were compared using a negative binomial regression model, and prevalence outcomes and measure of compliance with ITNs at the time of monthly assessments were compared using generalized estimating equations with adjustment for repeated measures. For all analyses, only the assigned treatment arm was included as a covariate, with the exception of a multivariate analysis performed for the primary outcome of malaria incidence, which also included age at randomization and incidence of malaria prior to randomization, covariates thought to be potential independent risk factors for malaria. Measures of association were expressed as protective efficacy (1 minus the incident rate ratio or prevalence ratio) during the intervention and incident rate ratios after the intervention was stopped. A P value less than 0.05 was considered statistically significant.
Ethics statement
Ethical approval was obtained from the Uganda National Council for Science and Technology, the Makerere University School of Medicine Research and Ethics Committee, and the University of California, San Francisco Committee on Human Research.
Results
Trial profile and baseline characteristics
We screened 205 children and 200 were enrolled ( Fig. 1 ). Of enrolled children, 14 (7.0%) were excluded before randomization, including seven who became infected with HIV. The 186 enrolled children were randomized to one of the four treatment arms at a median age of 10 months: 46 to no chemoprevention, 46 to monthly sulfadoxine pyrimethamine, 47 to daily trimethoprimsulfamethoxazole and 47 to monthly dihydroartemisininpiperaquine. Baseline characteristics were similar across treatment arms (Table 1) . Prior to randomization, the incidence of malaria was lower in children subsequently randomized to all three treatment arms than children randomized to no chemoprevention, although these differences were not statistically significant (Table 1) . Among the 186 infants who were randomized, 174 (95.5%) and 171 (91.9%) were followed-up to 24 months and 36 months of age, respectively ( Fig. 1) . At monthly assessments, 96.8% reported sleeping under an ITN the prior evening, without significant differences between the study arms (P ¼ 0.31).
Protective efficacy of chemoprevention regimens against malaria
From the time of randomization to 24 months of age, the incidence of malaria in the no chemoprevention group was 6.28 episodes per person-year (Table 2) . After adjusting for age at randomization and incidence of malaria prior to randomization, monthly dihydroartemisinin-piperaquine had the greatest protective efficacy against malaria [protective efficacy 69%, 95% confidence interval (95% CI) 53-80, P < 0.001], followed by daily trimethoprim-sulfamethoxazole (protective efficacy 49%, 95% CI 23-66, P ¼ 0.001). Monthly sulfadoxine pyrimethamine did not have significant protective efficacy compared with the no chemoprevention group (protective efficacy 9%, 95% CI -35 to 38, P ¼ 0.65). In comparison to daily trimethoprim-sulfamethoxazole, monthly dihydroartemisinin-piperaquine was associated with a marginally significant protective efficacy (protective efficacy 39%, 95% CI 0-62, P ¼ 0.05). In all four arms, the incidence of malaria increased with age and the protective efficacies in the daily trimethoprimsulfamethoxazole and monthly dihydroartemisininpiperaquine arms were greater for children 16 months or younger than for those 17-24 months of age (Table 2 The proportion of assigned doses of study medications administered at home based on diaries completed by the primary care givers were 93% for sulfadoxine pyrimethamine, 99% for trimethoprim-sulfamethoxazole and 96% for dihydroartemisinin-piperaquine. To further explore adherence among study participants randomized to monthly dihydroartemisinin-piperaquine, piperaquine blood concentrations were measured at the time of each episode of malaria. Among 82 episodes, 81 samples were available for analysis. For three episodes, piperaquine
Chemoprevention in HIV-exposed children Kamya et al. 2705 Weight-for-age Z-score <À2. levels were more than 100 ng/ml and the primary caregivers reported giving the dihydroartemisinin-piperaquine within the prior 24 h, suggesting the coincidental onset of malaria just before the scheduled time for monthly dihydroartemisinin-piperaquine dosing. For the remaining 78 samples, piperaquine levels were below the level of detection (<10 ng/ml) on the day malaria was diagnosed in 53% of episodes, suggesting that a complete dose of dihydroartemisinin-piperaquine was not administered in the previous month [31, 32] . Thus, despite caregiver reports to the contrary, our results suggest frequent nonadherence with study dosing schedules.
Protective efficacy of chemoprevention regimens against secondary outcomes
Overall, complicated malaria was uncommon. Of a total of 620 treatments for malaria during the intervention period, 18 (2.9%) were for complicated malaria; 10 for severe malaria (nine severe anaemia and one respiratory distress) and eight for danger signs (six single convulsions and two persistent vomiting). There were no significant differences in the incidence of complicated malaria, hospitalization, diarrhoeal illnesses, respiratory tract infections or the prevalence of moderate-to-severe anaemia or gametocytemia between the treatment arms ( Table 3 ). Monthly dihydroartemisinin-piperaquine was significantly protective against asymptomatic parasitemia compared with the no chemoprevention arm (protective efficacy 88%, 95% CI 48-91, P ¼ 0.001). Daily trimethoprim-sulfamethoxazole and monthly sulfadoxine pyrimethamine were not significantly protective against asymptomatic parasitemia ( Table 3 ).
The incidence of malaria was 9.08 episodes per personyear at risk among children 24-36 months of age who had not received chemoprevention (Table 3 ). Following the cessation of the interventions, the incidence of malaria was 6.75, 8.13 and 6.78 episodes per person-year for children who had been on monthly sulfadoxine pyrimethamine, daily trimethoprim-sulfamethoxazole and monthly dihydroartemisinin-piperaquine, respectively. There were no significant differences in these incidences, although there were trends towards a lower incidence in children randomized to sulfadoxine pyrimethamine or dihydroartemisinin-piperaquine. Similarly, there were no significant differences in the incidence of complicated malaria or hospitalizations between the treatment arms in the year after the interventions were stopped, although there were trends towards a lower incidence in children randomized to dihydroartemisinin-piperaquine (Table 3) .
Safety outcomes
Among those assigned to study drugs, there were 144 grade 3 or 4 adverse events, but only eight (5.6%) were classified as possibly related to study drugs (three for trimethoprim-sulfamethoxazole and five for dihydroartemisinin-piperaquine, Table 4 ). The incidence of grade 3 or 4 adverse events, anaemia and elevated temperature was significantly lower in the dihydroartemisininpiperaquine arm than in the control arm. The incidence of grade 3 or 4 anaemia was significantly lower in the TS arm than in the control arm (P ¼ 0.009). There were no significant differences in the incidence of serious adverse events between the treatment arms (Table 4 ).
Discussion
We evaluated the efficacy and safety of three different malaria chemoprevention strategies given to HEU children beyond the period of HIV exposure when trimethoprim-sulfamethoxazole prophylaxis is normally discontinued: continuation of daily trimethoprim-sulfamethoxazole; monthly sulfadoxine pyrimethamine; or monthly dihydroartemisinin-piperaquine. Despite the use of ITNs, the incidence of malaria in those discontinuing trimethoprim-sulfamethoxazole was remarkably high, at more than six episodes per person-year at risk from randomization to 24 months of age, and more than nine episodes per person-year at risk from 24 to 36 months of age. Monthly sulfadoxine pyrimethamine provided no significant protection against malaria. Continuation of daily trimethoprim-sulfamethoxazole prophylaxis reduced the incidence of malaria by 49%. Monthly dihydroartemisinin-piperaquine was the most effective regimen, reducing the incidence of malaria by 69% and the prevalence of asymptomatic parasitemia by 88%. None of the regimens provided significant protection against diarrhoeal illnesses or respiratory tract infections. All three regimens were well tolerated and there were no differences in the incidence of malaria between the treatment arms after the intervention was stopped.
Current WHO guidelines recommend discontinuation of trimethoprim-sulfamethoxazole prophylaxis in HEU children after breastfeeding cessation, assuming that the main benefit of prophylaxis is prevention of opportunistic infections, such as Pneumocystis pneumonia, if a child is infected with HIV [12] . Several studies have shown that a major benefit of trimethoprim-sulfamethoxazole prophylaxis in sub-Saharan Africa is prevention of malaria [15, 19, 20] , and that this benefit extends beyond immune reconstitution in HIV-infected children and adults on antiretroviral therapy [21, 22] . We previously showed that extending trimethoprim-sulfamethoxazole prophylaxis in HEU children beyond the period of HIVexposure was well tolerated and modestly efficacious at preventing malaria [23] . In the present study, daily trimethoprimsulfamethoxazole again provided modest benefit against malaria, without significant benefit against diarrhoeal or respiratory tract infections, suggesting that the main benefit in extending trimethoprim-sulfamethoxazole prophylaxis in HEU children in this setting is the prevention of uncomplicated malaria. The other intensive antifolate regimen studied, monthly sulfadoxine pyrimethamine, offered no significant protection against malaria, which may not be surprising given the high prevalence of mutations in Plasmodium falciparum target genes associated with antifolate resistance in Uganda [23, 33] . Monthly dihydroartemisinin-piperaquine was the most protective against malaria and asymptomatic parasitemia. Importantly, the true protective efficacies of all three studied regimens may have been underestimated, as treatments were not directly observed, and measurements of piperaquine blood levels suggested frequent noncompliance with chemoprevention regimens.
Overall, our results were not surprising given recent studies showing excellent protective efficacy of monthly dihydroartemisinin-piperaquine in African children [34, 35] , including a parallel study showing 58% protective efficacy of dihydroartemisinin-piperaquine compared with no chemoprevention in HIV-unexposed children in Tororo [30] .
We were also interested in the subsequent impact of chemoprevention after cessation of study drugs, given concerns that chemoprevention might delay the acquisition of antimalarial immunity, leading to a rebound in Chemoprevention in HIV-exposed children Kamya et al. 2707 the incidence of malaria after the intervention is stopped [36, 37] . Interestingly, recent studies of IPT have not been associated with a rebound in the incidence of malaria [25] , with one study showing a sustained reduction in the incidence of malaria in the year after the intervention was stopped, suggesting that IPT could actually enhance the development of naturally acquired immunity [38] . In the present study, in the year following the discontinuation of study drugs, the incidence of malaria was similar in children randomized to the three chemopreventive regimens and in children who had not received prior chemoprevention, suggesting that, in this high transmission setting, the use of chemopreventive regimens with a range of protective efficacies did not negatively impact the development of antimalarial immunity. Further, there were trends towards lower incidences of malaria, complicated malaria and allcause hospital admissions after cessation of chemoprevention in children randomized to monthly dihydroartemisinin-piperaquine, suggesting a more rapid acquisition of immunity in those children.
In conclusion, we found that, in an area of high-malaria endemicity, continuing daily trimethoprim-sulfamethoxazole or starting monthly dihydroartemisinin-piperaquine in HEU children from the time of breastfeeding cessation through 24 months of age had significant protective efficacy against malaria in comparison to the current standard of care, discontinuation of trimethoprim-sulfamethoxazole prophylaxis. Monthly dihydroartemisinin-piperaquine had the greatest protective efficacy, was well tolerated and was not associated with rebound in malaria morbidity in the 1 year following the intervention. Given the rising number of HEU children living in malaria endemic settings, our results argue strongly for continued malaria prophylaxis beyond the period of HIV exposure. Additional studies are needed to evaluate optimal chemoprevention strategies in breastfeeding children in the era of Option Bþ, as well as strategies to optimize treatment compliance and maintain surveillance for potential selection of drug-resistant parasites. 
